SCHEMBL874987

SCHEMBL874987

Cc1ccc2nnn(CCC(Sc3ccc(NC(=O)c4ccc(Cl)c(Cl)c4)cc3)C(=O)O)c(=O)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.49
CTNNB1 P35222 1/20 0.45
TCF7L2 Q9NQB0 1/20 0.45
GPR139 Q6DWJ6 2/20 0.40
RAB9A P51151 2/20 0.40
PTGDR2 Q9Y5Y4 4/20 0.40
POLB P06746 1/20 0.39
HTT P42858 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HSP90AA1 P07900 1/20 0.37
G6PD P11413 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875423 0.92 GPR139 (0.45) DGAT1GPR139RAB9APOLBHTT
SCHEMBL874661 0.89 CTNNB1 (0.44) DGAT1CTNNB1TCF7L2GPR139RAB9A
SCHEMBL878120 0.88 MAPT (0.46) DGAT1CTNNB1TCF7L2GPR139RAB9A
SCHEMBL874668 0.88 GPR139 (0.49) GPR139RAB9AKDM4EKMT2ALMNA
SCHEMBL15733086 0.86 GPR139 (0.44) GPR139RAB9ANPC1
SCHEMBL874885 0.86 GPR139 (0.48) DGAT1CTNNB1TCF7L2GPR139RAB9A
SCHEMBL878096 0.85 GPR139 (0.45) DGAT1GPR139RAB9APOLBHTT
SCHEMBL875589 0.84 GPR139 (0.49) DGAT1GPR139RAB9AHTTKDM4E
SCHEMBL878124 0.84 GPR139 (0.44) DGAT1GPR139RAB9APOLBHTT
SCHEMBL878389 0.84 CTNNB1 (0.45) DGAT1CTNNB1TCF7L2GPR139RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 DGAT1 888/4885CTNNB1 2748/4885TCF7L2 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.